Close
Smartlab Europe
Achema middle east

Yuvraj

AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414

AbbVie a global biopharmaceutical company, announced that the U.S. FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting...

Mylan NV Launches Generic Temodar Capsules

Mylan N.V. announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is...

Questex Acquires ExL Events

Questex, a leading global business information and events company announced it has acquired ExL Events, Inc., expanding Questex's presence in the global pharmaceutical, life...

EC Grants Marketing Authorization for Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C

Gilead Sciences, Inc announced that the European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet...

Sanofi and WRAIR sign research agreement to co-develop Zika vaccine candidate

Sanofi and its vaccines global business unit Sanofi Pasteur Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the...

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based...

FDA Approves Gilead’s Epclusa for the Treatment of All Genotypes of Chronic Hepatitis C

Gilead Sciences, Inc. announced that the U.S. FDA has approved Epclusa , the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

Translate »